SAN
DIEGO and WUHAN,
China, April 23, 2024 /PRNewswire/
-- HanxBio today announced that it has published a research
article titled "Narazaciclib, a novel multikinase inhibitor with
potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML
activity in defined preclinical models" in the Nature Portfolio
online journal Scientific Reports. Narazaciclib (HX301 or
ON123300) is a clinical stage small molecule investigational new
drug jointly developed by HanxBio and its business partner OncoNova
Therapeutics, Inc. (now Traws Pharma, Inc.). In this peer-reviewed
article, the researchers from HanxBio described comprehensive
pharmacology characterization of HX301 using a series of
preclinical experimental AML models, including in vitro cell
lines, and in vivo cell line-derived xenografts (CDXs) and
patient-derived xenografts (PDXs). The report demonstrated the
strong anti-leukemia activity of HX301 along with potential
mechanism of actions (MOAs), including the inhibition of
FLT3-ITD/TKD and potentially the inhibition of CSF1R, which is
demonstrated in a robust experimental system beyond inv(16) subset for the first time.
This report also studied the pharmacodynamics and pharmacokinetics
of HX301, including the relationship between drug exposure and
efficacy, which can be used to assist clinical dosage selection.
Some of these works were conducted in collaboration with Crown
Bioscience, Inc. and Kyinno Biotech, Ltd.
Dr. Henry Li, President/Chief
Scientific Officer of HanxBio and the corresponding author of this
article, commended: "In-depth preclinical and translational
research of HX301 helped us to identify clinical study indications
as well as appropriate dose(s), thereby accelerating clinical
development by increasing the probability of success. The results
of this study will guide our clinical development strategies for
HX301 for the treatment of AML."
About HanxBio, Inc.
HanxBio is a clinical stage biopharmaceutical company that
develops innovative new medicines, focusing on research and
development of precise innovative antibody, small molecule and
antibody-drug conjugate (ADC) new drugs for the treatment of
cancers and autoimmune diseases. The company's main scientific and
managerial team have many years of experiences in the
biopharmaceutical industries. HanxBio has built innovative drug
product pipelines both in the clinical stages and preclinical
stages.
About HX301
It is a small molecule multi-kinase inhibitor jointly developed
by HanxBio and its partner. It has completed phase I clinical
trials in the United States and
China, and it is currently been
investigated in phase II clinical trials for various indications in
China and the United States.
Media Inquiries:
HanxBio, Inc., Bruce Zhong:
cheng.zhong@hanxbio.com
View original
content:https://www.prnewswire.com/news-releases/hanxbio-announces-the-publication-of-a-research-paper-in-scientific-reports-on-preclinical-evaluation-of-narazaciclib-for-the-treatment-of-acute-myeloid-leukemia-aml-302124216.html
SOURCE HanxBio, Inc.